Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row

After William Blair and Piper Sandler gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst Arlinda Lee maintained a Buy rating on Crispr Therapeutics AG yesterday and set a price target of $80.00. The company’s shares closed last Monday at $60.38.

According to, Lee is a 3-star analyst with an average return of 1.7% and a 45.6% success rate. Lee covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Deciphera Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $73.78, representing a 35.1% upside. In a report issued on April 28, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $157K and GAAP net loss of $69.73 million. In comparison, last year the company earned revenue of $328K and had a GAAP net loss of $48.41 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts